OrganaBio, LLC

11/10/2025

Monday Team Highlight - Sarah Alter!

Sarah Alter, Ph.D., has over 15 years of immunology research experience which includes autoimmunity, cancer, and infectious disease.

Before her position at OrganaBio, Sarah was responsible for leading a team of scientists at Altor Bioscience where she facilitated the advancement of Altor’s technologies.

As a Research and Development Manager, Dr. Alter coordinated immunotherapy-focused preclinical and clinical studies and contributed to the progress of Altor’s drug discovery and therapeutic applications.

Sarah received her Doctor of Philosophy from the University of Miami, Miller School of Medicine. She is also a registered Patent Agent, licensed to practice before the United States Patent and Trademark Office.

Her work was published in many peer-reviewed journals and presented at national and international business and scientific meetings.

hashtag hashtag hashtag

10/20/2025

Monday Team Highlight - Ben Isaacson!

As a dedicated Customer Success Associate Manager, Ben is committed to enhancing customer experiences and addressing each customer’s unique needs.

Prior to OrganaBio, Ben championed customer needs for aerospace and military contractors at one of the largest over-the-road transportation providers in the US. His expertise in understanding and exceeding customer needs was honed during his tenure as a customer service representative.

Prior to that, Ben excelled as an outside sales representative for several years, further enriching his understanding of customer-centric strategies.

Before transitioning into the Customer Success role at OrganaBio, Ben was an Inside Sales Representative, allowing him to develop a deep understanding of the company’s portfolio of products and services and unique customer needs for which OrganaBio’s bespoke portfolio is designed.

Ben’s unwavering dedication to positive customer experiences is evident in his proactive approach to problem-solving and his ability to cultivate strong, long-lasting relationships.

With a relentless focus on delivering exceptional service, Ben aims to exceed expectations and delight the customer with every interaction.

His time in outside sales was in the firefighter and industrial safety industry.

Ben is a dad to three young daughters, so a majority of his free time is spent being a dad! However, he is big into hiking/backpacking/camping, and all things outdoors.

Ben is also an avid woodworker and does a lot of carpentry projects to remodel his very, very old house!

10/13/2025

Monday Team Member Highlight - Gabrielle Freitas!

Gabrielle Freitas completed her bachelor’s degree in Bioengineering at Universidade Estadual Paulista, Brazil, in 2021.

Following her academic achievements, she furthered her laboratory expertise through a molecular biology internship at Montgomery County Community College.

During this valuable experience, Gabrielle successfully developed a cell line expressing varying levels of the CD20 gene. Subsequently, Gabrielle transitioned to Integral Molecular, dedicating a year to antibody discovery before evolving into a role in sales and account management.

In her current role at OrganaBio, Gabrielle continues her journey in account management, connecting academia, biotech, and large pharmaceutical entities with our proprietary cellular starting materials obtained through a well-established supply chain.

This integrated expertise positions Gabrielle in the intersection of laboratory science, business development, and client relations.

Fun facts about Gabrielle: She loves traveling, modern art and painting, and she has a corgi named Korg!

10/06/2025

Monday Team Highlight!

Dr. Carlos Carballosa holds a doctorate in Biomedical Engineering from the University of Miami and currently leads global sales for OrganaBio as the VP of Sales.

Since joining the company in 2018, Carlos has had a hand in managing all of OrganaBio’s products and services including perinatal tissue, apheresis material, and cell processing and cryopreservation support services for clinical trials.

Some fun facts about Carlos:

1) He used to do thrifting

2) He wrote a manual on how to sell guitar hero controllers for profit - not going to see that every day!

10/01/2025

Why Cryopreservation Isn’t Just “Freezing Cells” - It’s Your Supply Chain’s Backbone

When starting materials like leukopaks or PBMCs go through inconsistent cold chains, you risk:

• Reduced viability
• Uneven recovery
• Batch-to-batch variability
• Wasted reagents and trial delays

That’s why effective cold-chain management matters — from donor collection to final thaw:

- Time to processing is critical (minimize delays post-collection)

- Use validated cryoprotectants and controlled-rate freezing protocols

- Monitor temperature continuously (alarms + redundancy)

One bonus few talk about: cryopreservation lets you decouple collection from processing, giving your program flexibility to scale and adapt without risking sample integrity

Learn more:

Advanced cell-based therapies, such as chimeric antigen receptor (CAR)-T cell therapies, are changing the landscape of healthcare, expanding treatment options for patients beyond previous standards of care in major disease areas. To ensure successful cell therapy outcomes, the timely and reliable de...

09/29/2025

Monday Team Highlight!

Jackie Gould is a recent graduate with a Bachelor of Science in biotechnology and two years of hands-on experience as a microbiology laboratory assistant.

Her experience in academic research and positive interpersonal skills have enabled her to seamlessly integrate theoretical knowledge into practical applications.

Known for her adaptability and innovative thinking, Jackie brings a fresh and vibrant energy to the biotech industry.

At OrganaBio, Jackie is dedicated to establishing meaningful client connections within the cell and gene therapy space to accelerate the worldwide adoption of revolutionary therapies.

Driven by her insatiable desire to help those around her, Jackie strives to create an environment where collaboration thrives.

Jackie enjoys being in nature, paddleboarding, hiking, horseback riding. Fun fact is that she has a horse named Hollywood!

09/22/2025

Ask most biotech teams what keeps them up at night before an IND, and they’ll say data. Are the results strong enough? Are they convincing?

But when regulators review an IND, the bigger obstacle often isn’t weak data - it is weak documentation.

The science can be groundbreaking, but if the pathway from donor material (in the case of allogeneic cell therapies for example) to final product isn’t clearly mapped, traceable, and reproducible, the IND package stalls.

The overlooked risks look like this:
• Data collected without the full audit trail regulators expect.
• Processes that were efficient in the lab but never fully documented for scale.
• Critical compliance records treated as an afterthought until submission day.

An IND submission isn’t just a scientific argument. It is a proof of control. It shows regulators that the process is not just effective once, but reliable every time.

The hard truth is that many programs are delayed not because of the science, but because of the systems around the science. Addressing that early is the fastest way to move forward

09/19/2025

One of the biggest surprises for early-stage biotech teams is how difficult it is to scale from research to GMP production.

The assumption is simple: take what worked in the lab, apply it to larger equipment, and keep moving forward.

The reality is very different. Processes that produce promising data at research scale often fall apart when brought into a GMP environment.
Why?

• Reproducibility. Research runs often tolerate more variability. GMP cannot. Every step must yield the same result, every time.

• Documentation. What passes for a note in a lab notebook has to become a validated, auditable record.

• Compliance. The standards for a clinical-grade product go far beyond “does it work.” They demand proof that it works the same way tomorrow, next week, and next year.

When teams underestimate this transition, they waste critical starting materials, repeat failed runs, and lose critical time.

The ones who succeed are those who treat scale-up as its own discipline, not just a bigger version of what came before.

Explore OrganaBio's cGMP manufacturing facility in Miami:
https://www.organabio.com/the-organabio-cgmp-manufacturing-facility/

09/17/2025

What happens to cord blood that's not banked for private or public use? Unfortunately, most of the time it gets discarded.

However, not everyone knows, but the blood and cells inside that cord are a valuable resource for cell therapy development.

We are grateful for our team at GaiaGift and the donors who choose to donate these otherwise discarded materials for further use.

Cord blood holds a large quantity of stem cells that possess the ability to mature into different blood and immune cells. Doctors have been using these cells for decades to treat serious conditions like leukemia, sickle cell anemia, and immune disorders.

Here's why it matters:

🩸Bone marrow is more difficult to match with cord blood stem cells, and thus transplants become safer.

🩸They can be stored for years and still remain effective.

🩸Researchers are looking into how they can make regenerative medicine and even new cell and gene treatments possible.

🩸Something that was once medical waste is now fueling treatments and innovation

Cord blood is more than a resource, it's a gift that takes one moment of birth and generates new possibilities at life.

Did you know that OrganaBio uses that blood to produce some of the important materials for future breakthroughs?

https://www.organabio.com/product-category/isolated-immune-cells/

09/15/2025

🩸 Biotech Basics: What is GMP and why does it matter?

If you’ve ever heard someone in biotech mention “GMP” and wondered why it matters so much, you’re not alone.

🩸 GMP stands for Good Manufacturing Practice.

It’s essentially the playbook that ensures therapies, vaccines, and cellular materials are made safely, consistently, and at the highest quality standards.

Here’s why GMP is so important:
Trust and Safety: Lives are on the line. Every batch of material must have high standards to ensure it is safe and effective.

🩸 Regulatory Approval: Agencies like the FDA require GMP for treatments to move forward. Without it, even groundbreaking science can't reach patients.

🩸 From Research to Patients: Crossing from research-grade to GMP-grade material is what makes it possible to go from discovery to real treatments.

🩸 Reliability for Researchers: GMP collected and manufactured materials aren't only compliant they assure us that results are replicable and scalable clinically compliant they are the foundation for auditability, traceability, standardized, and scalable results.

OrganaBio doesn't view GMP as red tape. We see it as the foundation of trust and quality. With our standalone facility, ethical donor protocols, and recallable donor inventory, we provide not just compliance, but confidence and continuity.

Because in biotech, GMP isn't about check-boxing - it's about bringing breakthroughs to life.

🩸 Learn more about our practices: https://www.organabio.com/the-organabio-cgmp-manufacturing-facility/

09/02/2025

It is clear that having new, reliable sources of fresh and frozen tissue and functioning processing capabilities isn't just advantageous, but important to staying on schedule with the new advances in the industry.

OrganaBio wants to support you in this mission.

That's why we were so thrilled to be involved in Scientist.com's Vendor Discovery Day in San Francisco and get to meet so many passionate researchers, innovators, and industry professionals. Everyone there shared one powerful mission: advancing life-saving therapies that can change lives.

We’re inspired to keep supporting this incredible community with fresh, reliable tissue supplies and tailored services that help push science forward faster and more confidently.

We can’t wait to keep the conversations going at the next event in Boston this year!

04/07/2024

Today, on World Health Day, we celebrate the founding of the World Health Organization (WHO) and their mission of ensuring health for all. OrganaBio supports all organizations working to improve global health outcomes, promote health equity, and prioritize health and well-being.